|
WO2020264509A1
|
|
Compositions and methods for treating cns disorders
|
|
WO2020264495A1
|
|
Compositions and methods for treating cns disorders
|
|
WO2020264512A1
|
|
Compounds for treating cns disorders
|
|
WO2020243488A1
|
|
Neuroactive steroids and compositions thereof
|
|
WO2020243027A1
|
|
Compounds, compositions, and methods of use
|
|
TW202038967A
|
|
Neuroactive steroids and compositions thereof
|
|
TW202039528A
|
|
Neuroactive steroids and their methods of use
|
|
TW202027754A
|
|
Neuroactive steroids and their methods of use
|
|
WO2020077255A1
|
|
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
|
|
AR115536A1
|
|
A C21-N-PYRAZOLYL 19-NOR C3,3-DISUSTITUTED STEROID AND METHODS OF USE OF THE SAME
|
|
WO2019241442A1
|
|
A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
|
|
WO2019140272A1
|
|
Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
|
|
EP3728284A1
|
|
Compositions and methods for treating cns disorders
|
|
AU2018392093A1
|
|
Compositions and methods for treating CNS disorders
|
|
US2020291059A1
|
|
Compositions and methods for treating cns disorders
|
|
WO2019075362A1
|
|
Method of treating cns disorders with neurosteroids and gabaergic compounds
|
|
WO2019075361A1
|
|
Method of screening compounds for treating cns disorders
|
|
AU2018334214A1
|
|
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
|
US2020276209A1
|
|
Methods of treating epilepsy or status epilepticus
|
|
EP3678670A1
|
|
Neuroactive steroids and their methods of use
|
